Teva Pharmaceutical Industries Limited (TEVA) Announces the Appointment of Professor Itzhak Krinsky as Chairman of Teva Japan and Teva South Korea and Head of Business Development in Asia-Pacific

Teva Pharmaceutical Industries Limited (TEVA) Announces the Appointment of Professor Itzhak Krinsky as Chairman of Teva Japan and Teva South Korea and Head of Business Development in Asia-Pacific

9/13/2012 10:31:42 AM

JERUSALEM--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the appointment of Professor Itzhak Krinsky as Chairman of Teva Japan and Teva South Korea and Head of Business Development Asia-Pacific. Currently serving as Executive Vice President, Corporate Business Development at Teva, Professor Krinsky's new appointment will be effective mid-October. Professor Krinsky will be responsible for overseeing Teva's generic and branded pharmaceuticals businesses in Japan and South Korea. Additionally, Professor Krinsky will manage Business Development for the Asia-Pacific region. He will continue to serve as a member of the Teva Executive Committee and will be located in Tokyo.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.